ClinicalTrials.gg
CompletedNCT01140581ARTEMIS LoadUpdated Jan 23, 2012

Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation

A Phase 4 interventional study of DRONEDARONE in Atrial Fibrillation, sponsored by Sanofi. Completed at 111 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-23.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
7th of 26
402 · median 164
Started
2010
with 8 others
Phase 4
11 of 26
2 open now
Registered
10th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 7th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 10th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

  • Evaluate the rate of Atrial Fibrillation (AF) recurrences one month after randomization according to different timings of initiation of dronedarone.

Secondary Objective:

  • Evaluate the rate of AF recurrences two months after randomization.
  • Assess the safety of the change from amiodarone to dronedarone
  • Assess dronedarone safety
  • Explore dronedarone and its active metabolite plasma level (in a subset of countries)
  • Explore potential Pharmacokinetic (PK) interaction between dronedarone and amiodarone (in a subset of countries)
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening:

  • Persistent AF for more than 72 hours (documented by an taken within the last 72 hours) for whom cardioversion, anti-arrhythmic treatment and anticoagulation treatment are indicated in the opinion of the Investigator
  • Naive of amiodarone treatment in the last three months
  • Bazett \< 500 ms on 12-lead ECG,
  • At least one cardiovascular risk factor (i.e. age > 70, hypertension, diabetes, prior cerebrovascular disease or left atrial diameter >= 50 mm

Randomization:

  • Outpatient and Inpatients (except patients hospitalized during screening period for SAE)
  • Sinus rhythm
  • Effective oral anticoagulation verified by /INR (target > 2)
  • QTc Bazett \< 500 ms and PR \< 280 ms on 12-lead ECG
  • Completed treatment period with amiodarone (28 days ± 2 days)

Exclusion criteria

Exclusion criteria:

Screening:

  • to oral anticoagulation
  • Acute condition known to cause AF
  • Permanent AF
  • Paroxysmal AF
  • Bradycardia \< 50 bpm on the 12-lead
  • Clinically overt congestive heart failure:

    • with (NYHA) classes III and IV heart failure
    • with \< 35%
    • or NYHA class II with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic
    • or unstable hemodynamic conditions
  • Severe hepatic impairment
  • Previous treatment with class I or class III anti-arrhythmic drugs (including sotalol) if taken less than one week
  • Previous history of amiodarone intolerance or toxicity
  • Any contraindication as per dronedarone and amiodarone labelling
  • Wolff-Parkinson-White Syndrome
  • Previous ablation for atrial fibrillation or any planned ablation in the next 2 months
  • Contraindicated concomitant treatment:

    • Potent cytochrome P450 () inhibitors
    • Use of drugs or herbal products that prolong the and known to increase the risk of Torsades de Pointes
    • Class I or III anti-arrhythmic drugs (including sotalol)

Randomization:

  • Bradycardia \< 50 bpm on the 12-lead ECG
  • Clinically overt congestive heart failure:

    • with New York Heart Association (NYHA) classes III and IV heart failure
    • with LVEF \< 35%
    • or NYHA class II with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic
    • or unstable hemodynamic conditions
  • Severe hepatic impairment
  • Previous treatment with class I or class III anti-arrhythmic drugs (including sotalol) if taken less than one week
  • Patient in whom the following contraindicated concomitant treatment is mandatory:

    • Potent cytochrome P450 (CYP3A4) inhibitors
    • Use of drugs or herbal products that prolong the QT interval and known to increase the risk of Torsades de Pointes
    • Class I or III anti-arrhythmic drugs (including sotalol)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    Group A

    Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks

    Drug: DRONEDARONE

  • Experimental
    Group B

    Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks

    Drug: DRONEDARONE

  • Experimental
    Group C

    Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks

    Drug: DRONEDARONE

Interventions

  • Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg

06

What researchers measure

Primary outcomes

  1. AF recurrences

    two consecutives 12-lead ECG or Trans-Telephonic ECG monitoring (TTEM) approximatively 10 minutes apart and both showing AF

    Time frame: one month after randomization

Secondary outcomes

  1. AF recurrences

    Time frame: two months after randomization

  2. Symptomatic bradycardia

    Heart rate at rest \< 50 beats per minute

    Time frame: two months after randomization

  3. Tachycardia

    Heart rate at rest \> 120 beats per minute

    Time frame: two months after randomization

  4. Dronedarone and amiodarone concentrations in plasma

    Limited to a subset of countries

    Time frame: 3 hours, 1 week, 2 weeks and 4 weeks after 1st Dronedarone intake

07

Study locations

111 sites
  • Investigational Site Number 009
    Adelaide, 5000, Australia
  • Investigational Site Number 013
    Ballarat, 3350, Australia
  • Investigational Site Number 002
    Garran, 2605, Australia
  • Investigational Site Number 007
    Herston, 4006, Australia
  • Investigational Site Number 012
    Hobart, 7000, Australia
  • Investigational Site Number 006
    Liverpool, 2170, Australia
  • Investigational Site Number 010
    Maroubra, 2035, Australia
  • Investigational Site Number 001
    Nedlands, 6009, Australia
  • Investigational Site Number 004
    New Lambton, 2305, Australia
  • Investigational Site Number 008
    Redcliffe, 4020, Australia
  • Investigational Site Number 011
    South Brisbane, 4101, Australia
  • Investigational Site Number 005
    Southport, 4215, Australia
  • Investigational Site Number 003
    Woolloongabba, 4102, Australia
  • Investigational Site Number 040-006
    Braunau, 5280, Austria
  • Investigational Site Number 040-007
    Innsbruck, 6020, Austria
  • Investigational Site Number 040-002
    Linz, 4010, Austria
  • Investigational Site Number 040-001
    Mödling, 2340, Austria
  • Investigational Site Number 040-003
    Vienna, Austria
  • Investigational Site Number 040-005
    Wien, 1090, Austria
  • Investigational Site Number 040-004
    Wien, Austria
  • Investigational Site Number 233001
    Tallinn, 10138, Estonia
  • Investigational Site Number 246-001
    Hyvinkää, 05850, Finland
  • Investigational Site Number 246-002
    Hyvinkää, 05850, Finland
  • Investigational Site Number 246-004
    Pori, 28210, Finland
  • Investigational Site Number 246-003
    Seinäjoki, 60220, Finland
  • Investigational Site Number 250-006
    Avignon Cedex 9, 84902, France
  • Investigational Site Number 250-009
    BEZIERS Cedex, 34525, France
  • Investigational Site Number 250-002
    Bron, 69677, France
  • Investigational Site Number 250-007
    Cholet, 49300, France
  • Investigational Site Number 250-008
    Lyon Cedex 03, 69275, France
  • Investigational Site Number 250-010
    NIMES Cedex 9, 30029, France
  • Investigational Site Number 250-003
    POITIERS Cedex, 86021, France
  • Investigational Site Number 250-004
    Toulouse Cedex 3, 31076, France
  • Investigational Site Number 250-005
    Valence Cedex 9, 26953, France
  • Investigational Site Number 250-001
    Vandoeuvre Les Nancy, 54511, France
  • Investigational Site Number 276-003
    Berlin, 13055, Germany
  • Investigational Site Number 276-006
    Bernau, 16321, Germany
  • Investigational Site Number 276-001
    Bonn, 53115, Germany
  • Investigational Site Number 276-011
    Dresden, 01099, Germany
  • Investigational Site Number 276-010
    Frankfurt am Main, 60594, Germany
  • Investigational Site Number 276-002
    Hamburg, 22041, Germany
  • Investigational Site Number 276-008
    Hamburg, 22527, Germany
  • Investigational Site Number 276-009
    Heidenau, 01809, Germany
  • Investigational Site Number 276-004
    Kiel, 24105, Germany
  • Investigational Site Number 276-005
    Ludwigsburg, 71634, Germany
  • Investigational Site Number 276-007
    Paderborn, 33098, Germany
  • Investigational Site Number 376002
    Ashkelon, Israel
  • Investigational Site Number 376001
    Beer Yaakov, Israel
  • Investigational Site Number 380-005
    Ancona, 60100, Italy
  • Investigational Site Number 380-002
    Barga, 55051, Italy
  • Investigational Site Number 380-004
    Catania, 95124, Italy
  • Investigational Site Number 380-001
    Como, 22100, Italy
  • Investigational Site Number 380-006
    Cortona, 52042, Italy
  • Investigational Site Number 380-011
    Mestre, 30174, Italy
  • Investigational Site Number 380-010
    Palermo, 90127, Italy
  • Investigational Site Number 380-007
    Roma, 00168, Italy
  • Investigational Site Number 380-003
    Roma, 00169, Italy
  • Investigational Site Number 380-009
    San Daniele Del Friuli, 33038, Italy
  • Investigational Site Number 380-012
    Varese, 21100, Italy
  • Investigational Site Number 410001
    Seoul, 152-703, Korea, Republic of
  • Investigational Site Number 410002
    Seoul, Korea, Republic of
  • Investigational Site Number 410003
    Seoul, Korea, Republic of
  • Investigational Site Number 410004
    Seoul, Korea, Republic of
  • Investigational Site Number 410005
    Seoul, Korea, Republic of
  • Investigational Site Number 410006
    Suwon, 443-721, Korea, Republic of
  • Investigational Site Number 484017
    Aguascalientes, 20230, Mexico
  • Investigational Site Number 484012
    Chihuahua, 31238, Mexico
  • Investigational Site Number 484008
    Guadalajara, 44200, Mexico
  • Investigational Site Number 484009
    Guadalajara, 44600, Mexico
  • Investigational Site Number 484015
    Guadalajara, 44600, Mexico
  • Investigational Site Number 484002
    Leon, 37150, Mexico
  • Investigational Site Number 484016
    Mexico, 06140, Mexico
  • Investigational Site Number 484004
    Mexico, 07760, Mexico
  • Investigational Site Number 484005
    Monterrey, 64460, Mexico
  • Investigational Site Number 484003
    Monterrey, 64710, Mexico
  • Investigational Site Number 484001
    Queretaro, 76000, Mexico
  • Investigational Site Number 484013
    Saltillo, 25230, Mexico
  • Investigational Site Number 484011
    Tijuana, 22450, Mexico
  • Investigational Site Number 528003
    Amsterdam, Netherlands
  • Investigational Site Number 528005
    Goes, Netherlands
  • Investigational Site Number 528002
    Groningen, Netherlands
  • Investigational Site Number 528001
    Maastricht, Netherlands
  • Investigational Site Number 528004
    Rotterdam, Netherlands
  • Investigational Site Number 620005
    Amadora, 2720-276, Portugal
  • Investigational Site Number 620001
    Lisboa, 1169-024, Portugal
  • Investigational Site Number 724004
    El Palmar (MURCIA), 30120, Spain
  • Investigational Site Number 724005
    Hospitalet de Llobregat, 08907, Spain
  • Investigational Site Number 724008
    La Coruña, 15006, Spain
  • Investigational Site Number 724003
    LLeida, Spain
  • Investigational Site Number 724010
    Madrid, 28034, Spain
  • Investigational Site Number 724001
    Madrid, 28040, Spain
  • Investigational Site Number 724002
    Majadahonda, 28222, Spain
  • Investigational Site Number 724006
    Sevilla, 41071, Spain
  • Investigational Site Number 724007
    Tarragona, 43007, Spain
  • Investigational Site Number 724009
    Valencia, 46014, Spain
  • Investigational Site Number 756001
    Basel, 4031, Switzerland
  • Investigational Site Number 756002
    St.Gallen, 9007, Switzerland
  • Investigational Site Number 158005
    Kaohsiung Hsien,, Taiwan
  • Investigational Site Number 158006
    Kaohsiung, 807, Taiwan
  • Investigational Site Number 158009
    Taichung City, Taiwan

Showing the first 100 of 111 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Naccarelli GV, Bhatt DL, Camm AJ, Le Heuzey JY, Lombardi F, Tamargo J, Martinez JM, Naditch-Brule L; ARTEMIS AF Investigators. Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):425-437. doi: 10.1177/1074248420926874. Epub 2020 Jun 5. PubMed 32500725 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2010
First posted
Jun 9, 2010
Start
Sep 2010
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Jan 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01140581
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 9, 2010
Start date
Sep 2010
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Jan 23, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion